Trevi Therapeutics (TRVI) Other Non-Current Liabilities (2018 - 2022)

Trevi Therapeutics' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $3000.0 for Q4 2022.

• On a quarterly basis, Other Non-Current Liabilities fell 97.37% year-over-year to $3000.0 in Q4 2022; TTM through Dec 2022 was $3000.0, a 97.37% decrease from a year earlier, with the FY2022 full-year figure at $3000.0, down 97.37% from the prior year.
• Other Non-Current Liabilities retreated to $3000.0 in Q4 2022 per TRVI's latest filing, from $15000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $1.1 million in Q4 2018 and bottomed at $3000.0 in Q4 2022.
• The 4-year median for Other Non-Current Liabilities is $125000.0 (2022), against an average of $197636.4.
• Biggest YoY gain for Other Non-Current Liabilities was 2.94% in 2022; the steepest drop was 97.37% in 2022.
• Year by year, Other Non-Current Liabilities stood at $1.1 million in 2018, then plunged by 82.12% to $196000.0 in 2020, then plunged by 41.84% to $114000.0 in 2021, then tumbled by 97.37% to $3000.0 in 2022.
• Per Business Quant, the three latest TRVI Other Non-Current Liabilities figures stand at $3000.0 (Q4 2022), $15000.0 (Q3 2022), and $35000.0 (Q2 2022).